IRG1-IN-1_product_DataBase

Bioactivity	IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases[1].
Invitro	IRG1-IN-1(compound 6) (0.5 mM; 2 mM) reduces production of itaconic acid and the secretion of TNFα from LPS-stimulated human monocyte derived macrophages (hMDMs) [1].IRG1-IN-1 (0.5 mM; 1 mM) inhibits the proliferation of C-IRG1-9 rat glioma cells[1].IRG1-IN-1(10 nM) increases proliferation of TCR-activated hCD8+ T cells[1].IRG1-IN-1(10μM) shows depletion of trimethylation of histone 3 at lysine 4 (H3K4me3) in CR-activated hCD8+ T cells[1]. Western Blot Analysis[1] Cell Line:
In Vivo	IRG1-IN-1 (compound 6) (i.p.; 0.2 mg/kg; 27 days) shows antitumor effect in C57BL/6 mice[1]. Animal Model:
Name	IRG1-IN-1
CAS	2407652-42-8
Formula	C18H15FO4
Molar Mass	314.31
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Reference	[1]. Adonia Papathanassiu, et al. Compositions and methods of using itaconic acid derivatives. Patent. US20210261495A1.

PeptideDB